Fostemsavir Production Cost Reports

The report provides a detailed analysis essential for establishing a Fostemsavir production plant. It encompasses all critical aspects necessary for Fostemsavir production, including the cost of Fostemsavir production, Fostemsavir plant cost, Fostemsavir production costs, and the overall Fostemsavir production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Fostemsavir production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Fostemsavir is an antiviral medication that is primarily used in the treatment of HIV infection. It is particularly used in patients who have advanced HIV and have not responded well to other treatments. It acts by inhibiting the attachment of the virus to healthy cells, which helps prevent the virus from entering and replicating within the body. It is also utilised in combination with other antiretrovirals for the treatment of multidrug-resistant HIV-1 infection in heavily treatment-experienced adults. Moreover, it is also being studied for potential use in treating other viral infections.

The primary factor that drives the market for Fostemsavir is its use as an antiretroviral medication used in the treatment of HIV-1 infection, which promotes its demand in the pharmaceutical industry. Its usage in combination with other antiretroviral drugs as part of a treatment regimen for people with multi-drug-resistant strains of HIV further fuels its demand in the medical and pharmaceutical industries.

Its demand as an alternative treatment to improve the quality of life and reduce viral load in HIV-infected patients also drives its market growth. The increasing global focus on managing chronic HIV cases and improving long-term patient care outcomes significantly contributes to market growth. Additionally, industrial Fostemsavir procurement is shaped by factors such as the availability and pricing of key intermediates, stringent regulatory approvals, and adherence to pharmaceutical quality standards. Technological improvements in synthesis, consistency in supplier performance, and global health initiatives targeting HIV treatment access also influence procurement decisions.

Raw Material for Fostemsavir Production

According to the Fostemsavir production plant project report, the major raw materials for Fostemsavir production include Aryl bromide, 3-methyl-1H-1,2,4-triazole, Copper(I) iodide, N,N-dimethylcyclohexanediamine, Lithium iodide (LiI) hydrate, Di-tert-butyl (chloromethyl) phosphate, Acetic acid, and Tris(hydroxymethyl)aminomethane (TRIS).

Production Process of Fostemsavir

The extensive Fostemsavir production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of Fostemsavir begins with the Ullmann coupling reaction of aryl bromide and 3-methyl-1H-1,2,4-triazole, using CuI and N,N-dimethylcyclohexanediamine as the catalyst and ligand to form piperazine. Then, residual copper is removed with ammonium pyrrolidine dithiocarbamate. The resulting product is treated with potassium hydroxide and lithium iodide hydrate to precipitate the lithium salt. A phosphoryloxymethyl prodrug group is then added to the lithium salt using di-tert-butyl (chloromethyl) phosphate, triethyl sodium, and potassium carbonate. After quenching, extraction, and removal of unwanted byproducts, the main intermediate is isolated. Finally, the tert-butyl phosphate ester is deprotected by hydrolysis with acetic acid to expose the phosphate group. Then, adding tris(hydroxymethyl)aminomethane (TRIS) in acetonitrile results in the formation of the TRIS salt of fostemsavir as the final product.

Fostemsavir is a prodrug and an HIV-1 attachment inhibitor that prevents viral entry into host cells by binding directly to the viral envelope glycoprotein gp120. It appears as a white crystalline powder when formulated as fostemsavir tromethamine salt. The molecular formula of the compound is C25H26N7O8P, and its molar mass is 583.5 g/mol. It has a density of around 1.60 g/cm3, and its boiling point is around 904.1 degree Celsius. Common adverse reaction is nausea, while severe adverse reactions include elevations in liver enzymes in patients co-infected with the hepatitis B or C virus, QT interval prolongation, and immune reconstitution syndrome. The solubility of the compound in water is >250mg/mL. It is recommended that therapy be initiated by physicians experienced in HIV management, and patients with hepatitis co-infection or cardiac disease should be monitored appropriately while handling the medication.